

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/877,802	06/06/2001	Reiko M. Nakamura	10960-0112	2453
23370 7	590 08/27/2002			
JOHN S. PRATT, ESQ			EXAMINER	
1100 PEACHT	STOCKTON, LLP REE STREET		GABEL, GAILENE	
SUITE 2800			ART UNIT	PAPER NUMBER
ATLANTA, GA 30309		1641	Q	
			DATE MAILED: 08/27/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

· ·	Application No.	Applicant(s)			
•	09/877,802	NAKAMURA, REIKO M.			
Office Action Summary	Examiner	Art Unit			
•	Gailene R. Gabel	1641			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply		ONTHO) FROM			
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, and If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by soon - Any reply received by the Office later than three months after the meanmed patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, however, may a roll. a reply within the statutory minimum of thirty eriod will apply and will expire SIX (6) MON tatute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on	<u>06 June 2001</u>				
,—	This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-20 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-20</u> are subject to restriction and/or election requirement. Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
 Certified copies of the priority documents have been received. 					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 					
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948 Information Disclosure Statement(s) (PTO-1449) Paper No. 	3) 5) Notice of I	Summary (PTO-413) Paper No(s) · Informal Patent Application (PTO-152)			

Application/Control Number: 09/877,802

Art Unit: 1641

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-8, drawn to transdermal delivery device, classified in class 424, subclass 1.33, for example.
 - II. Claims 9-16, drawn to method of detecting active disease, classified in class 435, subclass 32, for example.
 - III. Claims 17-20, drawn to immunogenic composition, classified in class 514, subclass 946, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case, application of immunogenic composition by device can be performed by intradermal injection.

Inventions I and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the

Application/Control Number: 09/877,802

Art Unit: 1641

particulars of the subcombination as claimed because the subcombination does not require a topical application device, i.e. adhesive, etc. The subcombination has separate utility such as for use as vaccine.

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the antigen and physiologically active solution can be used in assay for determining binding kinetics of the antigen in the presence of physiologically active solution.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, because the search required for Group I is not required for Group II, which is further not required for Group III, restriction for examination purposes as indicated is proper. Literature search for each method, apparatus, and composition is distinct since the structural requirements of each invention are different. While searches would be expected to overlap, there is no reason to expect the searches to be coextensive.

2. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 4

Application/Control Number: 09/877,802

Art Unit: 1641

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (703) 305-0807. The examiner can normally be reached on Monday to Thursday, 6:30 AM - 4:00 PM and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 308-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Gailene R. Gabel August 21, 2002

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800-7697

Christyel L. Chi